Clearpoint Neuro (CLPT) investor relations material

Executive summary

• Q2 2026 revenue grew 18% year-over-year to $10.9 million, driven by neurosurgery navigation and therapy product sales, particularly from the IRRAflow product and new navigation software, while biologics and drug delivery revenue declined 15% due to a non-recurring prior-year order and lower trial shipments.

• The acquisition of IRRAS in late 2025 expanded the product portfolio into neurocritical care and contributed to revenue growth.

• Expanded preclinical services at the new ClearPoint Advanced Laboratories (CAL), with the facility now operational and the first GLP study scheduled for H1 2027.

• Strategic focus shifted to clinical support, CAL facility ramp, and technology development, with commercial structure reorganized to support anticipated drug delivery readiness in 2027.

• Announced entry into focused ultrasound market via partnership with SONOCARE Lab and achieved preclinical proof-of-concept for blood-brain barrier delivery.

Financial highlights

• Q2 2026 total revenue: $10.9 million, up from $9.2 million in Q2 2025 (18% increase); six months ended June 30, 2026: $23.0 million (up 30%).

• Neurosurgery navigation and therapy revenue rose 62% to $5.6 million, driven by IRRAflow and new software.

• Capital equipment and software revenue increased 24% to $1.3 million.

• Gross margin improved to 62% in Q2 2026 from 60% in Q2 2025.

• Cash and cash equivalents were $29.4 million as of June 30, 2026, down from $45.9 million at year-end 2025, mainly due to $15 million operational cash burn.

Outlook and guidance

• 2026 revenue guidance revised to $48.0–$52.0 million, reflecting a shift in investment focus to clinical support, regulatory expansion, and technology development.

• Operational cash burn expected to decrease in the second half of 2026 as IRRAS integration completes.

• 2027 growth projected in the high teens to 20% range, with potential upside from CAL facility ramp and commercial drug delivery launches.

• Expectation of 10–15 clinical trials enrolling and ~10 partner data readouts in the next 18 months.

• Cash balances are considered sufficient to support operations and meet obligations for at least the next twelve months.